Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.

Life sciences - 1 Sept 2018

Qian Weikun, Li Jie, Chen Ke, Jiang Zhengdong, Cheng Liang, Zhou Cancan, Yan Bin, Cao Junyu, Ma Qingyong, Duan Wanxing

Abstract excerpt

AIMS: Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant diseases and has few effective and reliable therapeutic strategies. The anti-tumor effect of metformin is widely known, however, there is only limited evidence regarding the anti-angiogenesis effect and chemosensitization of metformin and its underlying mechanisms in PDAC. MAIN METHODS: In the present study, we adopted a spontaneous PDAC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Drug Synergism

Share to Gemcitabine

Share to Hypoglycemic Agents

Share to Metformin

Share to Neovascularization, Pathologic

Source

Identifiers

PMID: 30053447
DOI: 10.1016/j.lfs.2018.07.046

Genes

SHH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.PMID 30053447Read ↗

Effect of Stroma-directed Drugs in Combination with Chemotherapy Against Pancreatic Cancer- a Preclinical StudySemantic proximity Read ↗

The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models.Semantic proximity Read ↗

Genetically engineered mouse models of pancreatic adenocarcinomaSemantic proximity Read ↗

The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (<i>LSL‐Kras<sup>G12D/+</sup>;LSL‐Trp53<sup>R172H/+</sup>;Pdx‐1‐Cre</i>), Its Variants, and Their Application in Immuno‐oncology Drug DiscoverySemantic proximity Read ↗

Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncologySemantic proximity Read ↗

Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer.Semantic proximity Read ↗

Nestin Delineates Pancreatic Cancer Stem Cells in Metastatic Foci of NOD/Shi-scid IL2Rγnull (NOG) MiceSemantic proximity Read ↗

Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trialSemantic proximity Read ↗

Targeting eNOS in Pancreatic CancerSemantic proximity Read ↗

Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.Semantic proximity Read ↗

Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.